Treatments to cure chronic hepatitis B (HBV) infection are currently lacking. Here, the authors identify an HBV targeting siRNA that exhibits potent and broad-spectrum antiviral activity in preclinical animal models and demonstrates a favorable safety profile and functional cure indicators, promising clinical translation potential.
- Ze-Ao Huang
- Yang Yang
- Geng-Shen Song
